OriA 631 B
Alternative Names: OriA-631-BLatest Information Update: 20 Jul 2024
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD39 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2024 OriA 631 B is available for licensing as of 31 May 2024. https://www.oricell.com/en/about.html
- 31 May 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to May 2024
- 31 May 2024 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)